A judge has held that there could be favourable costs consequences for Carnival if its rejected $15 million settlement offer in the Ruby Princess class action turns out to be more generous than the ultimate damages award, departing from a previous ruling that so-called Calderbank offers do not operate in group proceedings.
A former Bureau of Meteorology senior executive was unfairly fired after taking a business-class trip to Paris, a court has found in a case that shines a light on the practice by government agencies to get around remuneration limits on public servants.
Two marine freight companies have lost a fight with a local council which refused to allow it to unload 3,000 head of cattle at Apollo Bay in Victoria, with a judge finding they were “the architects of their own misfortune” for striking a deal with a beef company before securing permission to berth at the port.
Calling all avid Lawyerly readers! Lawyerly is seeking nominations for its inaugural editorial advisory committee in 2024.
The High Court has agreed to step in to hear an appeal of a ruling that put a Federal Circuit and Family Court judge on the hook for a man’s false imprisonment.
Asylum seekers who were put in immigration detention in South Australia can transfer their cases to the Federal Court to run their claims as a class action accusing the federal government of negligence and unlawful detention.
The NSW Supreme Court has welcomed its newest judge, who was praised by his peers as “universally popular” for his warm personality and among the best tax silks in the country.
The High Court has refused special leave in a failed class action against Volkswagen over allegedly defective Takata airbags.
A former Greenwoods & Herbert Smith Freehills partner who alleges he was sacked for complaining about Lendlease’s “aggressive taxation position” has lost a bid to argue before the High Court that his claims are covered by new whistleblower protections.
South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson’s Janssen Biotech to invalidate two patents for Crohn’s disease drug Stelara, after reaching a licencing agreement over the medicine in the US.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
